Value based pricing could cost the NHS more


The planned new value based pricing system for approving drugs to be funded by the NHS could end up costing the NHS more, the Department of Health’s own impact assessment states.

You need to be an HSJ subscriber to read more


Subscribe to read the full article

With an HSJ subscription you’ll get access to:

  • Expert Briefing newsletters, covering nine topics and regions
  • Weekly Catch Up – a summary of the week’s most important stories
  • Unlimited access to
  • The HSJ app

Enquire about multi-user access